Novartis’ Cosentyx heads for fourth indicationNovartis’ Cosentyx could be heading for a fourth indication after the company published late-stage trial data showing it Share XNovartis’ Cosentyx heads for fourth indicationhttps://pharmaphorum.com/news/cosentyx-heads-for/
Amid tough competition, Novartis makes case for rheumatology drug CosentyxSwiss pharma hopes to bounce back from Q1 sales disappointment Share XAmid tough competition, Novartis makes case for rheumatology drug Cosentyxhttps://pharmaphorum.com/news/novartis-eric-hughes-cosentyx-secukinumab/
Lilly aims for new indication for TaltzEli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and Share XLilly aims for new indication for Taltzhttps://pharmaphorum.com/news/eli-lilly-aims-new-indication-il-17-drug-taltz/
